Professional Documents
Culture Documents
but......
REPORT CONTAINS
Interactive 820+ pages, divided into 6 Sections, with Infographics and Tables
2663
Indications In Trials
142
Cancer preclinical Pipeline Companies
462
Cancer Clinical Companies
210+
Cancer Targets
LatePreclinical Molecules
600+
1042
Molecules in Clinical Trials
Complete
2012
Cancer Drug Updates
Oncology Intelligence
462 COMPANIES
Division of Companies on the Basis of Market/Assets Valuation and Ownership, along with their country wise distribution.
Helps in identifying cancer research trends among Small, Mid & Large companies also as Public, Private & Subsidiaries, and nation wise preferences for the sector.
Division of Cancer Companies on the basis of employee numbers and Year of Incorporation.
Exploring cancer research funding needs and emergence of Cancer Drug Discovery Industry, going ahead.
Cancer Drugs in Development mAbs , Vaccines, mAbs-drug conjugates Gene Therapies & description of various others molecules.
2663 DRUG INDICATIONS in 19 CANCER TYPES Total 81 Pages with 53 Figures & 91 Tables
Division of total drug Indications among top 19 cancer subtypes (like Lung, Breast, Melanoma, etc.)
Helps in identifying the emerging vs. current Cancer Indications.
Orphan Drug Status molecules and their cancer indications (USFDA & EMEA). Oncology Clinical Pipeline Major Advances/Failures & New Entrants - 2012.
Total 16 Pages with 9 Tables Complete coverage of oncology focused events (1000+ events).
Profile contains Companys key management, key oncology assets (both clinical & preclinical), key collaborators, Investors, Molecules profile, targets & development strategies etc.
Only Oncology focused events are documented, to avoid any ambiguous data.
No Information is Duplicated.
The strongest point of Report, beside been precise is, no information is duplicated anywhere, that helps to avoid confusions/errors.
Oncology focused :- Key Highlights of Company, Key technology, Collaborations, partners, Approved pipeline, etc. Cancer Targeted Molecules in Clinical Development:Molecule name(s), Target, Clinical Phase, all possible Indications of development of the molecule, Last Updated on Clinical Trials with Trial Status as on Dec 2012 & Drug type (Small/Biologic/NBCM).
Management Profile: Contact Address, Founded Year, Ownership, Key Management People, Stock Ticker and Market Capitalization
Key Highlights of Drugs in Development :- Drugs Target Description, Mechanism of Action, Orphan Status, Preclinical Pipeline etc.
Total 95 Pages
Key Technology Platform. Key Technology Partners, Key Investors & other Company and Cancer Drug Highlights.
Highly Innovative Report contains all aspects of Oncology Drug Intelligence. First Infographics Report Figures can also be used in Presentations.
Largest Coverage First Report which covers 620+ companies with 1600+ molecules details and complete pipeline analysis. First Scientific Report which extensively focuses on technologies and drug targets. Precise Information All Efforts are done to reproduce Accurate Information.
Value for Money - The report is an excellent value for money, without
2799/- USD
Prior 28th Feb 2013 e-copy only. Including all taxes.
compromising the quality. This is all possible by reducing our marketing expenses (comprises nearly 60-70% of report cost) and utilizing more resources in developing quality content.
Opinion on Oncology Intelligence 2013: During Jan 2013, about 316 free preview copies of Oncology Intelligence 2013 were distributed to Industry leaders working in area of oncology drug development through LinkedIn invitation call and nearly all of them replied very positive on the report.
We are sharing few industry leaders comment on their consent. It is an excellent report that has a wide variety of oncology information all in one place.
Dr. Oleh Denysyk
This report contains enough data to make strategic decisions especially for new entrants.
Dr. Mitsuyoshi Nishizaki
Classic work esp. Section B with facts on oncology targets and drug alliances.
Dr. Shohko Iwami
Intelligent BioSolutions
OmicsX design and develop highly innovative comprehensive intelligence reports to provide complete 3600 view to its readers. Starting 2013, every second month we are lined up with knowledge centered reports in life science. Each report reflects Team OmicsX in-depth knowledge and innovative out of the box thinking. We works for several month to craft a single original content interactive report at very competitive price, with only one aim in mind to provide quality and precise information to our clients which will help in decision support. Reports contains Insights and analysis at the company, country and disease level, which includes individual companys profiles and market data, valuations, clinical & market trends, product pipelines and forecasts. For Details and Enquiries on our Customized Services, Contact
Virendra Singhvi
Manager Business Development virendra.singhvi@omicsx.com +1-646-523-4433 +44-203-608-3536 +91-562-2281122